Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle

British Journal of Dermatology, Supplement

Volumn 149, Issue 66, 2003, Pages 59-61

  Berman, B ^a   Sullivan, T ^a   De Araujo, T ^a   Nadji, M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Basal cell carcinoma; Fas receptor; Imiquimod

Indexed keywords

EOSIN; FAS ANTIGEN; GAMMA INTERFERON; HEMATOXYLIN; IMIQUIMOD; LIGAND;

ANTIGEN EXPRESSION; APOPTOSIS; BASAL CELL CARCINOMA; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXCISION; HUMAN; IMMUNOPEROXIDASE STAINING; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE;

EID: 0347951008     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0366-077x.2003.05634.x     Document Type: Conference Paper

References (14)

1. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-95.
2. Filipowicz E, Adegboyega P, Sanchez RL, Gatalica Z. Expression of CD95 (Fas) in sun-exposed human skin and cutaneous carcinomas. Cancer 2002; 94: 814-19.
3. Gutierrez-Steil C, Wrone-Smith T, Sun X, Krueger JG, Coven T, Nickoloff BJ. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B- irradiated psoriatic plaques express Fas ligand (CD95L). J Clin Invest 1998; 101: 33-9.
4. Buechner SA, Wernli M, Harr T et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas) -CD95 ligand induced suicide. J Clin Invest 1997; 100: 2691-6.
5. Testerman TL, Gerster JF. Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-2709. J Leukoc Biol 1995; 58: 365-72.
6. Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% cream (Aldara®). Exp Opin Invest Drugs 1998; 7: 437-49.
7. Imbertson LM, Beaurline JM, Couture AM et al. Cytokine induction in hairless mouse and rat skin after topical application of immune response modifiers imiquimod and S-2709. J Invest Dermatol 1998; 110: 734-9.
8. Dahl M. Imiquimod: an immune response modifier. J Am Acad Dermatol 2000; 43: S1-5.
9. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multi center 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
10. Geisse JG, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
11. Nadji M, Nassiri M, Fresno M et al. Laminin receptor in lymph node negative breast carcinoma. Cancer 1999; 85: 432-6.
12. Berman B, Sullivan T, de Araujo T, Vincek V, Elgart G. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Poster presented at the World Congress of Dermatology. Paris 2002; P2063.
13. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992; 327: 1649-62.
14. Drake LA, Ceilley RI, Cornelison RL et al. Guidelines of care for basal cell carcinoma. J Am Acad Dermatol 1992; 26: 117-20.